What Happens After TURBT Matters More Than You Think

April 2, 2026

Transcript

Voice over:

This is Bladder Cancer Matters, the podcast for bladder cancer patients, caregivers, advocates, and medical and research professionals. It’s brought to you by the Bladder Cancer Advocacy Network, otherwise known as BCAN. BCAN works to increase public awareness about bladder cancer, advances bladder cancer research, and provides educational and support services for bladder cancer patients and their loved ones. To learn more, please visit bcan.org.

Rick Bangs:

Hi, I’m Rick Bangs, the host of Bladder Cancer Matters, a podcast for, by and about the bladder cancer community. I’m also a survivor of muscle-invasive bladder cancer, the proud owner of a 2006 model year neobladder and a patient advocate supporting cancer research at the Bladder Cancer Advocacy Network, or as many call it, BCAN, producers of this podcast. I’m pleased to welcome today’s guest, Dr. Mohummad Siddiqui. Dr. Siddiqui is a urologic oncologist at the University of Maryland, where he is a professor of surgery, as well as director of urologic oncology and director of robotic surgery. He also leads research that is testing the use of diet to improve cancer outcomes and the use of imaging to better identify and ultimately treat urologic cancers. In addition, he has significant interest in quality improvement work and has engaged nationally in these endeavors. Dr. Siddiqui has held leadership roles within the American Neurologic Association, the AUA; the American College of Surgeons; the Commission on Cancer; the Society of Basic Urologic Research; and the American College of Radiology. Dr. Siddiqui, thanks for joining our podcast.

Dr. Minhaj Siddiqui:

Oh, thank you for having me.

Rick Bangs:

We are very pleased to have you. So important topic and the focus is going to be on non-muscle-invasive bladder cancer today and how often some of these patients get treated the treatment that’s specified in the guidelines. So can you start by giving us a quick refresher on non-muscle-invasive bladder cancer, its prevalence, its behavior, how it’s managed, risk stratification, things like that.

Dr. Minhaj Siddiqui:

Yeah, wonderful. So I think that today we’re talking about what is in the bladder cancer world actually the most common form of cancer. We split localized bladder cancer into non-muscle-invasive bladder cancer and muscle-invasive bladder cancer because the treatment methods really verge between the two. About 70 to 75% of newly diagnosed bladder cancers are non-muscle-invasive bladder cancers. And so these, in terms of more technical aspects, are your stage TA, T1, CIS, carcinoma in situ tumors essentially with TA being not invading any structure simply on the lining, the urothelium of the bladder. T1 is invading this layer one layer below the lining, the lamina propria.

The next layer below is muscle, and so by definition, if the tumor is invading that area, that’s called muscle-invasive bladder cancer. This is a disease state that is characterized by high recurrence rate. About 50 to almost 70% of patients who are diagnosed or treated actually initially with non-muscle-invasive bladder cancer will have to deal with it in a future date. And some subset of these patients actually do progress to more aggressive cancers such as muscle-invasive bladder cancers. And so I think usually we do risk stratification as low, intermediate, and high risk, and take it from there. Usually the first thing we do is actually set patients up for resection, and well, I’m sure we’ll talk about that in a minute, but that’s kind of, I think, the starting point for this.

Rick Bangs:

Okay. And that’s exactly where we’re going to go. So we’re going to talk about this TURBT, which is the transurethral resection of the bladder tumor, and it’s really a cornerstone for a bladder cancer treatment. So what constitutes a good TURBT?

Dr. Minhaj Siddiqui:

Yeah. So look, TURBT is the kind of fundamental foundational treatment that initiates one’s journey in terms of treatment and cure for bladder cancer, especially non-muscular-invasive bladder cancer. So typically speaking, as a urologist, one, the urologist should be trying to perform a complete visual resection of all visible tumor in the bladder when performing this procedure. The goal is to not only resect the tumor, but adequately sample the tissue below the tumor. And so this is how I alluded to the kind of staging of bladder cancer and how there’s a TA, T1, T2, and that depends on the layer of invasion. So you want to sample those layers. You want to get a little bit of muscle included within the scraping of the tumor, and that will give us an accurate kind of staging and grading. We want to send all of those samples to pathology, and that ultimately then helps not only treat the patient, but also accurately risk stratify them for future management decisions.

Rick Bangs:

Right. But you’re also balancing that with not perforating the bladder, right? So that’s kind of the constraint there. Okay. So which patients are supposed to receive chemo along with their TURBT, specifically talking about along with, and are these the same chemotherapy drugs that patients would receive prior to a radical cystectomy?

Dr. Minhaj Siddiqui:

So this is, I think, a growing, very hot topic in terms of really trying to optimally manage patients with non-muscle-invasive bladder cancer. So some really hallmark studies have been done in terms of giving chemotherapy in the bladder. So when we’re talking about chemotherapy around the time of TURBT for non-muscle-invasive bladder cancer, we are talking about intravesical. Intra being inside, vesicle being the medical term for bladder. So inside the bladder chemotherapy. This is to kind of compare it against systemic chemotherapy, which is chemotherapy that goes through your entire body system. So in other words, through the veins and in the blood. So this is not the same as that.

Intravesical chemotherapy should be given within 24 hours. Guidelines are within 24 hours, and often it’s given within just an hour or two. It’s given usually… Often a urologist will leave a Foley catheter in the patient after they’re done with their procedure, and they will actually either put the chemotherapy in the bladder and clamp off the tube while the patient’s still in the OR, so actually while they’re still asleep, or after they’re awake, but in the recovery area, so not far after the surgery.

There are two common agents that are used, mitomycin and gemcitabine. In recent years, gemcitabine has increasingly become more favored because it’s a little safer and more tolerable in terms of patients that we really try to target. The optimal benefit is in patients who have low and intermediate risk muscle-invasive bladder cancer. Really anyone can get it, but the people who are going to benefit most from it are the ones who have low and intermediate risk non-muscle-invasive bladder cancer.

Rick Bangs:

Okay. So now how did adding these particular chemos with a TURBT become standard of care?

Dr. Minhaj Siddiqui:

So there’s actually a pretty longstanding history of studies going back as far as 10 years. And so today, the guideline to give chemotherapy after TURBT is incorporated in the AUA, American Urologic Association Guidelines for Management of Bladder Cancer, the NCCN Guidelines as well, which is a national guideline setting body, National Comprehensive Cancer Network. There was kind of a pivotal trial that was published a few years ago in which patients… When we talk about trials, we talk about different kind of levels of evidence, and the highest level of evidence is called a randomized clinical trial where half the patients are randomly given one treatment and the other half are given the comparison treatment.

So half the patients got just saltwater saline in their bladder and half the patient’s got gemcitabine. And that way we pretty much are getting a comparison of what the benefit is of this treatment. And so gemcitabine versus saline, this was called the SWOG 0337 trial, and this trial demonstrated a 47% decrease in recurrence of the bladder cancer. It was a really… I mean, as good as outcomes get in cancer studies, almost half as likely to get cancer recurrence if you get this treatment after TURBT versus you don’t. And so that type of data, other studies have demonstrated similar outcomes, so it’s been repeatedly demonstrated to be beneficial. These are kind of fundamentally the ways that it’s become standard of care.

Rick Bangs:

Excellent. So I think most patients would wonder why do they need chemo if you’ve just removed their tumor using the TURBT? So can you explain a little bit about that?

Dr. Minhaj Siddiqui:

Couple of things. So we are, as urologists… When I say we, urologists, are trying to remove all the visible tumor, and so we have various tools. The optics are very nice nowadays in the equipment that we have. There’s also kind of supplemental things we can even use, blue light cystoscopy and whatnot, trying to find as much tumor as possible. But at the end of the day, there’s a limit to what you can see. There’s microscopic disease. Bladder cancer, we call it like a field cancer, meaning that when you have one area that is demonstrating cancer, often other areas in the field will ultimately manifest cancer as well. And so yes, the surgery is removing visible disease, but it may not capture disease that is too small to see.

Also, the logistics of how a tumor is removed, it’s scraped off the surface. There is a potential for some cells to break part during the mechanical disruption of scraping it off the surface and re-seed in the bladder. And so giving chemo immediately after surgery is thought to potentially interfere with the reseeding effect and also kill any residual tumor cells that might still be in the bladder or developing in the bladder.

Rick Bangs:

Okay. All right, so some listeners might be questioning, so where does BCG now fit into this treatment plan?

Dr. Minhaj Siddiqui:

Yeah, because it is confusing. BCG is also an intravesical treatment. It’s more of an immunotherapy, you can think of it. But the key difference is some treatments are designed to be given after the patient has fully healed from their surgery. BCG is one of them because BCG has some infection risks associated with it and you would not want to give it… It’s not safe to give immediately after there’s a kind of a procedure done and there’s a raw surface still there.

Rick Bangs:

All right, open wound.

Dr. Minhaj Siddiqui:

Yeah, open wound, if you will. Exactly. You can get infection of that wound with BCG. And so whether it’s BCG or other treatments that are given in future… For high-risk bladder cancer, for example, there’s often a plan to give intravesical treatments where people get an induction course of six treatments weekly, once weekly for six weeks in a row, and then maintenance course and all this type of thing. So many patients who listen to this podcast may be familiar with this or in the middle of doing these types of things. And there’s lots of treatments you can get, BCG is one of them, gemcitabine with docetaxel is another one that’s often given. There’s things out there. There’s the newer treatments that are coming out such as Adstiladrin and Anktiva, and the list kind of goes on. There’s a whole bunch of things. All of those are also intravesical therapies, but they are given in a slightly different context and with different timing and goals versus this particular situation, which is a one-time thing after a procedure.

Rick Bangs:

Okay. All right, so we’ve got the standard of care. It’s in the guidelines, as you’ve mentioned. It says these chemos come right after the TURBT for this group of non-muscle-invasive bladder cancer patients, but how often is it actually being done that way in the real world?

Dr. Minhaj Siddiqui:

I find this topic fascinating and I also find this topic really interesting because I believe there’s a lot we can do here to actually globally improve the way care is delivered to bladder cancer patients in the United States. And so this is a little bit how I think the two of us got connected on this topic altogether. So I, over the last few years, have been involved with various initiatives in particular with the American College of Surgeons and a organization within American College of Surgeons called Commission on Cancer, which is a quality body. It’s an accreditation organization that hospitals join to ascribe to certain high levels of quality of cancer care delivery.

And one of the things that we focused on, especially in my role as a urologist participating in this organization, is we wanted to look at urologic cancer quality measures, and in bladder cancer, we were looking at what are some measures that can measure how good the quality of care delivery is at various institutions. And after really kind of a two to three year long process with a large group, like a team of multidisciplinary cancer specialists from around the country, we honed in on this topic as one of a very reliable and meaningful quality measure. One of the quality measures that all national COC institutions have ascribed to is the measure of how often in patients who have TURBT with non-muscle-invasive bladder cancer, do they end up getting chemotherapy in their bladder within 24 hours?

The nice thing is when you do work with an organization… And I mentioned COC and American Surgeons, but I also want to point out that American Urologic Association has actually been very helpful as well, and many of the members doing this work have been kind of part of both overlapping groups. One of the things that happens when you have a quality measure like this is the infrastructure of these organizations also has data gathering and data recording, tumor registrars at every institution. There’s actually 1,500 institutions like this, 1,500 institutions around the country who are part of this infrastructure, the COC. 70% of cancer care in the United States is delivered within one of these institutions in the United States.

And so there is data being gathered essentially on 70% of cancer patients in the United States. And we can actually not only say this is a good idea, but we can actually look at how often is it being done. It’s all being gathered. And so when we looked at it, we found out that only 30% of patients in the United States who had this diagnosis of low risk non-muscle-invasive bladder cancer, patients who really should generally be getting chemotherapy were actually getting it. And it’s tricky because with quality measures, it’s not going to be a hundred. The goal is not to get it up to a hundred because there are valid situations where someone may not qualify for the chemo after TURBT. Sometimes if the resection is too deep or there’s too much bleeding, if they have an allergy, certain other medical issues, they may not be well-suited for the chemotherapy. But certainly the thought is that the compliance should be higher than 30%. So that’s where we’re at right now. That’s the current state that current guideline concordant care has room for improvement.

Rick Bangs:

So you’ve confirmed 100% is not the target. We are currently in the 30% range, so we want to do better. So let’s talk about… And you talked about some of the good reasons or some legitimate reasons, let me call it that, for not being at 100%, but are there other reasons that don’t fall into this it’s okay kind of thing that would help explain this gap?

Dr. Minhaj Siddiqui:

Totally. And this is where quality improvement comes in.

Rick Bangs:

Right, exactly.

Dr. Minhaj Siddiqui:

This is where we really can make some benefits. So it turns out it sounds like it shouldn’t be too hard, just after a person has a surgery, go ahead and give some chemotherapy in the bladder. You’re in a medical center. Turns out it’s actually pretty complicated. And when you start kind of diving deep into this, you realize that… So chemotherapy is generally made in a cancer pharmacy, which is not always closely associated with the OR pharmacy. And so there’s logistic issues with coordination, communication and timing that when a patient comes in, they have to be consented for the chemotherapy as well as part of the process. That has to be built into the workflow.

When the procedure is done, a decision is made in real-time that the chemotherapy is going to be given or not. So it’s not something that you can do some planning, but a lot of the decision making is actually happening in real-time. And so the system has to be agile and it has to be efficient in order for this to come together because a decision is made during the procedure and then the whole sequence of things have to be activated while the procedure is being completed or shortly after the procedure is completed. In parallel, someone needs to have the chemotherapy ready, has to get it transported to where the patient is. And actually whenever chemotherapy is involved, there’s actually specialized training that’s necessary with the staff, and there’s specialized disposal kind of requirements and all kinds of stuff.

So a site that is efficiently and kind of reliably giving chemotherapy after TURBT has actually gone through a whole lot of coordination and optimization of their processes to land at that outcome. That’s really actually what we started to kind of realize. And that’s why we suspect that it’s been hard nationally to get to this point. And some of the things that we’ve done as part of trying to understand this issue better is we looked at like, well, how do sites distribute? And it turns out that sites either are doing very poorly or quite well, which speaks to this possibility that there’s just all this kind of initial energy that needs to go into solving a lot of problems. And once you get them solved, you should be actually able to do a pretty good job at this, but you just need that push to get you over the hump.

Rick Bangs:

Okay. So there’s not like this even distribution. You’ve got a group of folks that are not doing as well and a group of folks that are doing well, and there’s less going on between the two groups.

Dr. Minhaj Siddiqui:

Yeah.

Rick Bangs:

Excellent. That’s fascinating. All right. So you’re leading what I consider to be an exciting and important study in this context. So tell us about the goal for your study.

Dr. Minhaj Siddiqui:

I started this journey getting involved with cancer measures. How do we measure quality care? It’s just something I’ve always been interested in the academic work that I do, because I’m an academic faculty, so I care for patients with these diseases, but I also study them and make things better and understand how to make things better. So it started off by saying, well, how do we even measure what good quality care is? And then we came to this measure and it became very clear that not only is this a good measure, but this is potentially an intervenable measure. So this falls under the space of quality improvement. And so that organization that I mentioned, the Commission on Cancer and American College of Surgeons, they actually have really interesting activity, not only in the accreditation of quality standards, but also they do quality improvement.

And actually one of the things that COC does is every year for all member institutions across the country, one of the things… Every institution that’s a member of this organization has to do accreditation activities every year. Part of their accreditation activity is to do a quality improvement project in the cancer space. It can be any cancer. And all institutions are free to either come up with their own quality improvement project or the COC provides one kind of package project for them to consider doing, just to make it easier. Because these institutions, it’s not just academic center, there are rural centers, suburban centers. They’re all part of this umbrella process.

Rick Bangs:

Which we want. We want that to be… Wonderful.

Dr. Minhaj Siddiqui:

Yeah. Man, many of these hospitals, they don’t have the resources really and infrastructure or expertise to put together their own thing, but they’re more than happy to take a package that’s kind of all laid out and kind of a guide on how to do a good QI project and then implement it at their site. And so I actually started talking with the leadership of the QI team and pitching… They’ve never done a urologic cancer project actually before. They’ve done other cancers in lung and rectal and breast, but the organization had never done a national QI project. They do one a year, and so it just kind of floats between the different topics. But I was like, “You know what?” We started floating the idea of doing a national QI project on this topic, intravesicular delivery of chemotherapy after bladder cancer. And they were super supportive. They wanted to see the feasibility.

So we actually ended up doing a small feasibility study within the University of Maryland medical system hospitals. So we got five of our system hospitals on board and did some testing of figuring out how to design a QI project and kind of got a lot of the nuts and bolts worked out on how to roll this out on a national level. As of last month, February, we kicked off the national campaign. So at this point, 232 hospitals across the country have signed on to participate in this national QI project, and all of these hospitals will be focusing on looking at their current compliance with this quality measure and what they need to do to improve their performance in this space. So it’s a one-year coordinated process. We’re expecting each hospital probably to have 30 to 40 patients. So we’re looking at upwards of 10,000 patients over the course of the year benefiting from this intervention, hopefully. It’s a very large scale exciting project and hoping that it’ll have fairly substantial impact in this space.

Rick Bangs:

10,000. That’s a lot.

Dr. Minhaj Siddiqui:

Yeah, it’s crazy. I mean, when you start doing study on the scale, the numbers start just getting huge. It’s really exciting. And assuming that it all kind of plays out, it’s really rewarding to be part of something on this level and scope, especially when you think about it. If only 30% of those patients were getting chemo and we can increase that number to 70%, which is, I think, a very reasonable target. Once the center focuses on this topic, I think they can get up to 70% pretty reliably. We’re looking at many thousands of people who may avoid tumor recurrence because we just got things working better.

Rick Bangs:

This is incredible. All right, so you’re at the University of Maryland and you’re obviously participating. You mentioned the pilot that was done there, and you mentioned there’s, I think you said 230-some-odd hospitals. So who are some of these partners that you’re working with?

Dr. Minhaj Siddiqui:

Actually, I think I’m not supposed to mention specific names.

Rick Bangs:

Oh, okay.

Dr. Minhaj Siddiqui:

Yeah, I think there’s some guides around that, but really there’s a couple things one can do if they’re kind of interested in knowing that if the hospital and the medical center that they go to is part of this global infrastructure. Probably the easiest thing a patient can do is you can search to see if your hospital is a COC hospital. It’s as easy as just searching on Google COC member hospital, and then one of the first things you’ll see will be a link to search if your hospital is a COC hospital. And then you can also just ask your urologist. I mean, they may not actually know if they’re part of COC hospital, but they certainly will know if they’re part of this process.

And some centers… The thing is not every center’s participated because many centers actually are doing a great job already, and if you’re already doing a good job, you don’t necessarily need to focus on this. So some places actually have already paid attention to this and have already come along with it. Because like I said, there was this layer of hospitals actually doing a great job. They already kind of seemed to have focused on this and figured it out. And then there’s a lot that didn’t, and that’s what we’re hoping to really benefit.

Rick Bangs:

All right, let’s close the gap here. Okay, talk about your timeline. Is it around a year, when do you have results?

Dr. Minhaj Siddiqui:

The way this project is structured, it literally just kicked off a few weeks ago and there’s three phases. So each phase is about three months or so. So everything will wrap up by December and we hope to collate the results, bring it all together. It takes a few months to study. So I’m hoping around this time next year, we will know what the outcome was. And I’ve already started… Right now, we don’t really know where we’re going to go with this next, but the infrastructure and the team and the coordination of efforts that we’ve been able to build as a side benefit of everyone coming together on this, what is I think globally recognized as an important topic has been wonderful.

And so we’re also looking at… So this is called the TApT, T-A-P-T, Timely Administration post-TURBT QI study. And so we’re looking for what does after TApT look like essentially, and see if we can actually continue using this momentum to actually make further improvements and further benefits and further understand nuances regarding the behavior and management of non-muscle-invasive bladder cancer. So hopefully there’ll be a lot to talk about not only one year from now, but two years from now and five years from now, but that’s what we’re looking at.

Rick Bangs:

Okay. All right. And you have an open invitation to come back and tell us what the results are because I think our listeners will be interested.

Dr. Minhaj Siddiqui:

It would be my honor. I love this media. I love this specifically your podcast and the audience that you reach. There’s not that many things out there that actually are catering for this group, and I love these types of opportunities to connect with the people who are most affected by the disease. So I appreciate the opportunity.

Rick Bangs:

And you’re gifted in doing so. Talk about why quality initiatives like this are important to patients.

Dr. Minhaj Siddiqui:

It’s an interesting thing, a quality initiative. To some extent, most physicians… I mean, all of us are participants in the endeavor to improve quality. I think that if you’re kind of a thoughtful person trying to do a good job, you’re trying to improve quality. But a structured quality initiative like this, I think it’s beneficial because like I mentioned, I think that there are sometimes slightly significant hurdles in the way between where you want to be and where you currently are. And if you just get over that hurdle, you actually end up in a pretty good place. And I think that there are certain things with intravesical chemo, after TURBT being one of them, where if you just get over the hurdle of getting all the team members aligned and getting all the resources and everything kind of just coordinated, the system that you will have in place after that on the other side of that barrier should be pretty durable and pretty sustainable without that much extra effort.

But the effort is in that one-time effort to get it over the hump. So a QI initiative where… Especially because look, I mean, I say surgeons are busy people, but actually everyone’s busy. And so when it falls on an individual, it’s hard to do. And so a urologist may be really interested in doing this, but it’s hard for them to do alone because this involves nursing and pharmacy and a lot of expertise that’s not quite in the ballpark, not in the wheelhouse of just an individual surgeon. It’s a coordinated effort of administrators and different team members and different teams and all kinds of people.

And so a QI initiative aligns organizational and group resources to focus on one problem at a time. And I think especially in problems that solving that problem will get you to a new level and let you stay there, that’s prime target for this type of work. That’s what makes this type of thing important. It really gives an opportunity for places to not have just the immediate short-term impact, what we’re talking about… And in this case, even the short-term impact is really exciting. If we can impact 10,000 patients, even if it ends up being 7,000, I mean, still, it’s all very exciting. But beyond that, I think we’re really excited to see, well, and what about two years from now and five years? What if this not only impacts the people that enroll in the study this year, but everyone getting care at those medical centers for the next five years? So I think that’s where this gets even more exciting.

Rick Bangs:

Plus I have to believe there’s going to be downstream effects in the bladder space and other urologic spaces and maybe beyond that by doing this study. It seems like there would be some nice byproducts.

Dr. Minhaj Siddiqui:

Yeah, you would hope so. Yeah, exactly. I think that it has brought about people who find work like this exciting and interesting, and it aligns really well with what we do in our day jobs anyways. So absolutely right, it’s a great point.

Rick Bangs:

Okay. All right. Any final thoughts?

Dr. Minhaj Siddiqui:

Mainly, I really appreciate the opportunity to share this with the audience that you have. I think in terms of what I would leave the patient audience with is that you too are kind of empowered to influence how this goes. I think by learning about these things and asking about them, it’s actually a positive reinforcement on [inaudible 00:31:46]. When you have heard about this type of thing and ask them, “What are your thoughts on the intravesical chemo after bladder? And do you do it? Do you not do it? If not, why not?”

Rick Bangs:

Right, right. Am I getting mitomycin or gemcitabine or not getting one of them at all?

Dr. Minhaj Siddiqui:

Yeah. And this type of thing, it’s like chances are if it’s not being done, it’s usually not being done at a center not because the physician doesn’t want to do it, but because logistically it’s been challenging. And sometimes getting that reinforcement that this is important to them and it’s on their radar is just enough extra motivation to not only encourage the physician to take a little bit of action, but for them to go to their organizational support structures and say, “You know what? Look, we haven’t been doing this and I want to do it. Can you help me?”

Ultimately, one of the things I’ve learned is I, myself… I’m new to this space. I mentioned I’m an academic, but I’ve been a clinical trial and basic science research physician scientist, and I actually was not trained up in the quality improvement space. It’s actually a new space for me that I’ve slowly made my way into. And it’s a whole world of implementation research and whatnot. It’s a very interesting and rigorous space. One thing that I’ve learned is these things are done in teams. They’re not done by individuals. And sometimes what you need is the encouragement to get that team mobilized, and that can come from an organization such as we have with this national QI initiative, but it also can come from patients saying, “This is important to us and can you do this?” And then you take that back to your hospital and your organizational leadership and say, “Look, patients are asking for this. They want this. We got to figure out how to do this.”

Rick Bangs:

Excellent. This is wonderful. So Dr. Siddiqui, I want to thank you for helping us understand the importance of chemotherapy after TURBT for non-muscle-invasive bladder cancer patients and the need for improvement in this space.

Dr. Minhaj Siddiqui:

No, thank you and thank you for the opportunity to talk about this topic.

Rick Bangs:

If you would like more information on bladder cancer, please visit the BCAN website, www.bcan.org. In case people wanted to get in touch with you, could you share some contact information?

Dr. Minhaj Siddiqui:

Yeah, absolutely. I think social media is particularly, I think, a good medium for me. So the one that I probably use most often is Twitter. I guess it’s not called Twitter, it’s called X, but my handle is @M-M-S-I-D-D-I-Q-U-I-MD. Again, that’s @mmsiddiquiMD.

Rick Bangs:

Okay. Wonderful. Just a reminder, if you’d like more information about bladder cancer, you can contact the Bladder Cancer Advocacy Network at 1-888-901-2226. That’s all the time we have today. Please like, comment, and subscribe so we have your feedback. Thank you for listening, and we’ll be back soon with another interesting episode of Bladder Cancer Matters. Thanks again, Dr. Siddiqui.

Dr. Minhaj Siddiqui:

Thank you.

Voice over:

Thank you for listening to Bladder Cancer Matters, a podcast by the Bladder Cancer Advocacy Network, or BCAN. BCAN works to increase public awareness about bladder cancer, advanced bladder cancer research, and provide educational and support services for bladder cancer patients. For more information about this podcast and additional information about bladder cancer, please visit bcan.org.